Usefulness of chitosan in the treatment of obesity and some of its comorbidities
Keywords:
CHITOSAN, OBESITY, ANTI-OBESITY DRUGS.Abstract
Introduction: in the search for products that allow or contribute to the loss of body weight with a minimum of adverse reactions, the use of various preparations of different origins has been considered, one of them being chitosan.
Objective: to describe the usefulness of chitosan in the treatment of obesity and some of its comorbidities.
Methods: a descriptive bibliographic review was carried out. Google and Google Scholar were used as search engines. Information from different databases was used. The keywords used were: chitosan; chitosan; chitosan; obesity; anti-obesity drugs (in English and Spanish). Articles were evaluated, which in general were less than 10 years old, in the referred languages and which by title dealt with the topic of study. 43 articles were referenced.
Results: chitosan is a natural biopolymer of glucosamine, it is biodegradable, biocompatible, non-toxic, and has hypolipidemic, anti-inflammatory, antidiabetic, antioxidant biological effects, and as a nutritional supplement for weight loss, among other applications. However, the review of the literature does not support this latter approach, although its usefulness as an adjuvant in the treatment of obesity and the cardiometabolic comorbidities that usually accompany it is recognized.
Conclusions: chitosan is a natural product that is not useful to obtain the long-awaited weight loss in obese patients. Although, it is useful as an adjuvant in its treatment, since it contributes to not increasing body weight and improves some of the cardiometabolic abnormalities associated with this disease.
Downloads
References
1. Gómez JC, Ena J, Lorido JA, Ripoll JS, Carrasco FJ, Gómez R, et al. La obesidad es una enfermedad crónica. Posicionamiento del grupo de trabajo de Diabetes, Obesidad y Nutrición de la Sociedad Española de Medicina Interna (SEMI) por un abordaje centrado en la persona con obesidad. Revista Clínica Española [Internet]. 2021 [Citado 18/08/2023]; 221(9): 509-16. Disponible en: https://www.sciencedirect.com/science/article/abs/pii/S0014256520301806
2. Pablo AM, García R, Leija G. Tratamiento farmacológico de la obesidad. Humanidades, tecnología y ciencia, del Instituto Politécnico Nacional [Internet]. 2020 [Citado 18/08/2023]; 22: 1-13. Disponible en: http://revistaelectronica-ipn.org/ResourcesFiles/Contenido/23/CIENCIA_23_000869.pdf
3. Di Marco MV, Posadas L, Valentí LL, Barrionuevo E, Bichara P, Incarbone O, et al. Guía de Práctica Clínica Nacional sobre Diagnóstico y Tratamiento de la Obesidad en adultos para todos los niveles de atención [Internet]. Ministerio de Salud, Presidencia de la Nación (Argentina); 2017 [Citado 12/07/23]. Disponible en: https://iah.salud.gob.ar/doc/Documento3.pdf
4. Rubio MA. Nuevas aproximaciones farmacológicas al tratamiento de la obesidad. Nutr Clin Med [Internet]. 2022 [Citado 12/7/23]; XVI(3): 179-94. Disponible en: https://nutricionclinicaenmedicina.com/wp-content/uploads/2022/12/5114.pdf
5. Agencia española de medicamentos y productos sanitarios. Ficha técnica Saxenda 6 mg/ml solución inyectable en pluma precargada [Internet]. CIMA; 2019 [citado 12/6/23]. Disponible en: https://cima.aemps.es/cima/dochtml/ft/115992003/FT_115992003.html#3
6. VADEMECUM. Semaglutida [Internet]. España; 2021 [Citado 02/07/2022]. Disponible en: https://www.vademecum.es/principios-activos-semaglutida-A10BJ06
7. Hernández J. La semaglutida en el tratamiento de las personas con diabesidad. Revista Cubana de Medicina [Internet]. 2023 [Citado 12/7/23]; 62(1). Disponible en: https://revmedicina.sld.cu/index.php/med/article/view/2946
8. Clément K, van den Akker E, Argente J, Bahm A, Chung WK, Connors H, et al. Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials. Lancet Diabetes Endocrinol [Internet]. 2020 [Citado 12/7/23]; 8(12): 960-70. Disponible en: https://www.thelancet.com/journals/landia/article/PIIS2213-8587(20)30364-8/fulltext
9. Navarro M, Jáuregui I. Tratamiento farmacológico de la obesidad. JONNPR [Internet]. 2020 [Citado 03/07/2023]; 5(12): 1464-69. Disponible en: https://jonnpr.com/PDF/3636.pdf
10. DAILYMED. Qsymia - phentermine and topiramate capsule, extended reléase. National Library of Medicine (NIH) [Internet]. AILYMED; 2022 [Citado 12/07/23]. Disponible en: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=40dd5602-53da-45ac-bb4b-15789aba40f9#S1
11. Aymara A, Nathaly P. Estudio de la hepatotoxicidad inducida por la ingesta de productos adelgazantes [Tesis]. Quito; 2022 [Citado 22/07/23]. Disponible en: http://www.dspace.uce.edu.ec/bitstream/25000/29585/1/UCE-FCQ-CBC-AGUIRRE%20PAMELA.pdf
12. Hernández J, Orlandis N. Spirulina platensis en el tratamiento de la obesidad y de algunas de sus consecuencias. Rev Cubana Med Gen Integr [Internet]. 2021 [Citado 18/08/2023]; 37(3): e1508. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0864-21252021000300016&lng=es.
13. Hernández J. Spirulina as a natural product with potentials for its use in patients with diabetes mellitus. Rev Cubana Endocrinol [Internet]. 2021 [Citado 18/08/2023]; 32(1): e247. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1561-29532021000100009&lng=es.
14. Hernández J, Iglesias I. Effects of Moringa oleifera on Human Health. Rev Cubana Med Gen Integr [Internet]. 2022 [Citado 18/08/2023]; 38(1): e1682. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0864-21252022000100017&lng=es.
15. Hernández J, Iglesias I. Moringa oleifera: un producto natural con posibilidades para ser usado en pacientes con diabetes mellitus. Rev Cubana Endocrinol [Internet]. 2021 [accedido 18/8/2023]; 32(1): e273. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1561-29532021000100011&lng=es.
16. Sutthasuphaa P, Lungkaphin A. Las funciones potenciales del oligosacárido de quitosano en la prevención de la lesión renal en condiciones de obesidad y diabetes. Food & Function [Internet]. 2020 [Citado 18/08/2023]; 11(9): 7371-88. Disponible en: https://pubs.rsc.org/en/content/articlelanding/2020/fo/d0fo00302f/unauth
17. Navarro R. Chitosán: qué es y para qué sirve [Internet]. Mifarma; 2022 [Citado 18/08/2023]. Disponible en: https://www.atida.com/es-es/blog/diccionario-farmacia/chitosan/
18. Huq T, Khan A, Brown D, Dhayagude N, He Z, Ni Y. Sources, production and commercial applications of fungal chitosan: A review. Journal of Bioresources and Bioproducts [Internet]. 2022 [Citado 28/08/2023]; 7(2): 85-98. Disponible en: https://www.sciencedirect.com/science/article/pii/S2369969822000020
19. Kou SG, Peters LM, Mucalo MR. Chitosan: A review of sources and preparation methods. International Journal of Biological Macromolecules [Internet]. 2021 [Citado 28/08/2023]; 169: 85-94. Disponible en: https://www.sciencedirect.com/science/article/abs/pii/S0141813020351631
20. Azmana M, Mahmood S, Hilles AR, Rahman A, Arifin MAB, Ahmed S. A review on chitosan and chitosan-based bionanocomposites: Promising material for combatting global issues and its applications. International journal of biological macromolecules [Internet]. 2021 [Citado 28/08/2023]; 185: 832-48. Disponible en: https://www.sciencedirect.com/science/article/abs/pii/S0141813021014604
21. Aranaz I, Alcántara AR, Civera MC, Arias C, Elorza B, Heras Caballero A, et al. Chitosan: An overview of its properties and applications. Polymers [Internet]. 2021 [Citado 28/08/2023]; 13(19): 3256. Disponible en: https://www.mdpi.com/2073-4360/13/19/3256
22. Baker WL, Tercius A, Anglade M, White CM, Coleman CI. A meta-analysis evaluating the impact of chitosan on serum lipids in hypercholesterolemic patients. Ann. Nutr. Metab [Internet]. 2009 [citado 18/8/2023]; 55(4): 368-74. Disponible en: https://karger.com/anm/article-abstract/55/4/368/40590/A-Meta-Analysis-Evaluating-the-Impact-of-Chitosan?redirectedFrom=fulltext
23. Tzeng HP, Liu SH, Chiang MT. Antidiabetic Properties of Chitosan and Its Derivatives. Mar Drugs [Internet]. 2022 [Citado 28/08/2023]; 20(12): 784. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9782916/
24. Kou SG, Peters L, Mucalo M. Chitosan: A review of molecular structure, bioactivities and interactions with the human body and micro-organisms. Carbohydrate Polymers [Internet]. 2022 [Citado 14/08/2023]; 282: 119132. Disponible en: https://www.sciencedirect.com/science/article/abs/pii/S0144861722000364
25. Hamedi H, Moradi S, Hudson SM, Tonelli AE, King MW. Chitosan based bioadhesives for biomedical applications: A review. Carbohydrate Polymers [Internet]. 2022 [Citado 14/08/2023]; 282: 119100. Disponible en: https://www.sciencedirect.com/science/article/abs/pii/S0144861722000042
26. Jafernik K, Ładniak A, Blicharska E, Czarnek K, Ekiert H, Wiącek AE, et al. Chitosan-Based Nanoparticles as Effective Drug Delivery Systems—A review. Molecules [Internet]. 2023 [citado 14/08/2023]; 28(4): 1963. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9959713/
27. Issahaku I, Tetteh IK, Tetteh AY. Chitosan and chitosan derivatives: Recent advancements in production and applications in environmental remediation. Environmental Advances [Internet]. 2023 [Citado 14/08/2023]; 11: 100351. Disponible en: https://www.sciencedirect.com/science/article/pii/S266676572300011X
28. Pal P, Pal A, Nakashima K, Yadav BK. Applications of chitosan in environmental remediation: A review. Chemosphere [Internet]. 2021 [citado 14/08/2023]; 266: 128934. Disponible en: https://www.sciencedirect.com/science/article/abs/pii/S0045653520331313
29. Market analysis report. Chitosan Market Size, Share & Trends Analysis Report By Application (Pharmaceutical, Water Treatment, Cosmetics, Biomedical, Food & Beverage), By Region, And Segment Forecasts, 2023 – 2030 [Internet]. Grand View Research; 2023 [citado 18/8/2023]. Disponible en: https://www.grandviewresearch.com/industry-analysis/global-chitosan-market
30. Huq T, Khan A, Brown D, Dhayagude N, He Z, Ni Y. Sources, production and commercial applications of fungal chitosan: A review. Journal of Bioresources and Bioproducts [Internet]. 2022 [citado 14/08/2023]; 7(2): 85-98. Disponible en: https://www.sciencedirect.com/science/article/pii/S2369969822000020
31. Bauer JL, Villegas LF, Zucchetti A. Aplicaciones del quitosano en la agricultura, la industria y la salud: Applications of chitosan in agriculture, industry and health. South Florida Journal of Environmental and Animal Science [Internet]. 2022 [citado 14/08/2023]; 2(2): 37–45. Disponible en: https://ojs.southfloridapublishing.com/ojs/index.php/sfjeas/article/view/1335/1084
32. Shahrajabian MH, Chaski C, Polyzos N, Tzortzakis N, Petropoulos SA. Sustainable agriculture systems in vegetable production using chitin and chitosan as plant biostimulants. Biomolecules [Internet]. 2021 [citado 14/08/2023]; 11(6): 819. Disponible en: https://www.mdpi.com/2218-273X/11/6/819
33. Wang J, Zhuang S. Chitosan-based materials: Preparation, modification and application. Journal of Cleaner Production [Internet]. 2022 [citado 18/8/2023]; 355: 131825. Disponible en: https://www.sciencedirect.com/science/article/abs/pii/S0959652622014354
34. Blázquez E, Sánchez R. Tratamiento de la obesidad en adultos: Liraglutida [Tesis]. Facultad de Farmacia de la Universidad complutense de Madrid; 2019 [citado 14/07/2023]. Disponible en: http://147.96.70.122/Web/TFG/TFG/Memoria/ELVIRA%20BLAZQUEZ%20MARCOS.pdf
35. Pittler MH, Abbot NC, Harkness EF, Ernst E. Randomized, double-blind trial of chitosan for body weight reduction. European Journal of Clinical Nutrition [Internet]. 1999 [citado 14/07/2023]; 53(5): 379-381. Disponible en: https://www.nature.com/articles/1600733
36. Mhurchu CN, Dunshea‐Mooij C, Bennett D, Rodgers A. Effect of chitosan on weight loss in overweight and obese individuals: a systematic review of randomized controlled trials. Obesity reviews [Internet]. 2005 [citado 14/07/2023]; 6(1): 35-42. Disponible en: https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1467-789X.2005.00158.x
37. Jull AB, Mhurchu CN, Bennett DA, Dunshea‐Mooij CA, Rodgers A. Chitosan for overweight or obesity. Cochrane database of systematic reviews [Internet]. 2008 [citado 14/07/2023];(3): CD003892. Disponible en: https://pubmed.ncbi.nlm.nih.gov/18646097/
38. Mhurchu CN, Poppitt SD, McGill AT, Leahy FE, Bennet DA, Lin RB, et al. The effect of the dietary supplement, Chitosan, on body weight: a randomised controlled trial in 250 overweight and obese adults. International Journal of Obesity [Internet]. 2004 [citado 14/07/2023]; 28(9): 1149-1156. Disponible en: https://www.nature.com/articles/0802693
39. Fatahi S, Sayyari AA, Salehi M, Safa M, Sohouli M, Shidfar F, et al. The effects of chitosan supplementation on anthropometric indicators of obesity, lipid and glycemic profiles, and appetite-regulated hormones in adolescents with overweight or obesity: A randomized, double-blind clinical trial. BMC pediatrics [Internet]. 2022 [citado 14/07/2023]; 22(1): 527. Disponible en: https://bmcpediatr.biomedcentral.com/articles/10.1186/s12887-022-03590-x
40. Rizzo M, Giglio RV, Nikolic D, Patti AM, Campanella C, Cocchi M, et al. Effects of chitosan on plasma lipids and lipoproteins: A 4-month prospective pilot study. Angiology [Internet]. 2014 [citado 14/07/2023]; 65(6): 538-542. Disponible en: https://journals.sagepub.com/doi/abs/10.1177/0003319713493126
41. Moraru C, Mincea MM, Frandes M, Timar B, Ostafe V. A meta-analysis on randomised controlled clinical trials evaluating the effect of the dietary supplement chitosan on weight loss, lipid parameters and blood pressure. Medicina [Internet]. 2018 [citado 14/07/2023]; 54(6): 109. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6306953/
42. Garmendia Lorena F. El síndrome metabólico, ¿artificio o realidad? An. Fac. med [Internet]. 2020 [citado 14/07/2023]; 81(1): 92-98. Disponible en: http://www.scielo.org.pe/scielo.php?script=sci_arttext&pid=S1025-55832020000100092&lng=es.
43. Fragozo MC. Síndrome metabólico: revisión de la literatura. Medicina & Laboratorio [Internet]. 2022 [citado 14/07/2023]; 26(1): 47-62. Disponible en: https://dialnet.unirioja.es/servlet/articulo?codigo=8741857
Downloads
Published
How to Cite
Issue
Section
License
Authors who have publications with this journal agree to the following terms: Authors will retain their copyrights and grant the journal the right of first publication of their work, which will be publication of their work, which will be simultaneously subject to the Creative Commons Attribution License (CC-BY-NC 4.0) that allows third parties to share the work as long as its author and first publication in this journal are indicated.
Authors may adopt other non-exclusive license agreements for distribution of the published version of the work (e.g.: deposit it in an institutional telematic archive or publish it in a volume). Likewise, and according to the recommendations of the Medical Sciences Editorial (ECIMED), authors must declare in each article their contribution according to the CRediT taxonomy (contributor roles). This taxonomy includes 14 roles, which can be used to represent the tasks typically performed by contributors in scientific academic production. It should be consulted in monograph) whenever initial publication in this journal is indicated. Authors are allowed and encouraged to disseminate their work through the Internet (e.g., in institutional telematic archives or on their web page) before and during the submission process, which may produce interesting exchanges and increase citations of the published work. (See The effect of open access). https://casrai.org/credit/
